Publication: Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
dc.contributor.author | Pasqualini, Claudia | |
dc.contributor.author | Furtwangler, Rhoikos | |
dc.contributor.author | van-Tinteren, Harm | |
dc.contributor.author | Teixeira, Roberto A P | |
dc.contributor.author | Acha, Tomas | |
dc.contributor.author | Howell, Lisa | |
dc.contributor.author | Vujanic, Gordan | |
dc.contributor.author | Godzinski, Jan | |
dc.contributor.author | Melchior, Patrick | |
dc.contributor.author | Smets, Anne M | |
dc.contributor.author | Coulomb-L'Hermine, Aurore | |
dc.contributor.author | Brisse, Herve | |
dc.contributor.author | Pritchard-Jones, Kathy | |
dc.contributor.author | Bergeron, Christophe | |
dc.contributor.author | de-Camargo, Beatriz | |
dc.contributor.author | van-den-Heuvel-Eibrink, Marry M | |
dc.contributor.author | Graf, Norbert | |
dc.contributor.author | Verschuur, Arnauld C | |
dc.contributor.funder | German CancerAid | |
dc.contributor.funder | Spanish Association Against Cancer (AECC) | |
dc.contributor.funder | Cancer Research UK | |
dc.date.accessioned | 2023-02-08T14:42:21Z | |
dc.date.available | 2023-02-08T14:42:21Z | |
dc.date.issued | 2020-03-05 | |
dc.description.abstract | High-risk (HR) metastatic (stage IV) Wilms tumours (WTs) have a particular poor outcome. Here, we report the results of HR (diffuse anaplastic [DA] or blastemal type [BT]) stage IV WT treated patients according to the HR arm in the SIOP2001 prospective study. From January 2002 to August 2014, 3559 patients with WT were included in the SIOP2001 trial. Among the 525 patients (15%) with metastatic WT, 74 (14%) had stage IV HR-WT. The median age at diagnosis was 5.5 years (range: 1.4-18.3). Thirty-four patients (47%) had BT-WT and 40 (53%) had DA-WT. Five-year event-free survival rates were 44 ± 17% and 28 ± 15% for BT-WT and DA-WT, respectively (p = 0.09). Five-year overall survival rates were 53 ± 17% and 29 ± 16% for BT-WT and DA-WT, respectively (p = 0.03). Metastatic complete response after preoperative treatment was significantly associated with outcome in univariate and multivariate analyses (hazards ratio = 0.3; p = 0.01). Postoperative radiotherapy of metastatic sites might also be beneficial. Forty-three of 74 patients experienced a relapse or progression predominantly in the lungs (80%). The median time to relapse/progression after diagnosis was 7.3 months (range: 1.6-33.3) and 4.9 months (range: 0.7-28.4) for BT-WT and DA-WT, respectively (p = 0.67). This is the first prospective evidence of inferior survival of stage IV BT-WT as compared with historical intermediate-risk WT. Survival of patients with stage IV DA-WT has not improved compared to the previous SIOP93-01 study. These results call for new treatment approaches for patients with HR stage IV WT. | |
dc.description.sponsorship | This work was partly funded by the German CancerAid (Deutsche Krebshilfe, grant No: 50-2709-GR2), Association Léon Berard Enfant Cancéreux and Enfant et Santé (Albec), The DaDa Society (Nieuwerkerk a/d Ijssel, The Netherlands), The Paediatric Oncology Centre Society for Research (KOCR, Rotterdam, the Netherlands), Grupo Cooperativo Brasileiro para o Tratamento do Tumour de Wilms (GCBTTW), Spanish Association Against Cancer (AECC), Cancer Research UK (grant refs: C1010/A2889 & C1188/A8687), and National Cancer Research Network support to UK centres for data management, as well as Elterninitiative Krebskranker Kinder im Saarland (Germany) for continuous data management of GPOH centres. | |
dc.description.version | Si | |
dc.identifier.citation | Pasqualini C, Furtwängler R, van Tinteren H, Teixeira RAP, Acha T, Howell L, et al. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group. Eur J Cancer. 2020 Mar;128:38-46 | |
dc.identifier.doi | 10.1016/j.ejca.2020.01.001 | |
dc.identifier.essn | 1879-0852 | |
dc.identifier.pmid | 32109849 | |
dc.identifier.unpaywallURL | https://discovery.ucl.ac.uk/10093818/16/Pritchard-Jones_Outcome%20of%20patients%20with%20stage%20IV%20high-risk%20Wilms%20tumour%20treated%20according%20to%20the%20SIOP2001%20protocol_AAM2.pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/15181 | |
dc.journal.title | European journal of cancer (Oxford, England : 1990) | |
dc.journal.titleabbreviation | Eur J Cancer | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Regional de Málaga | |
dc.page.number | 38-46 | |
dc.provenance | Realizada la curación de contenido 30/04/2025 | |
dc.publisher | Elsevier | |
dc.pubmedtype | Clinical Trial | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Research Support, Non-U.S. Gov't | |
dc.relation.projectID | 50-2709-GR2 | |
dc.relation.projectID | C1010/A2889 | |
dc.relation.projectID | C1188/A8687 | |
dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(20)30002-2 | |
dc.rights.accessRights | Restricted Access | |
dc.subject | Anaplasia | |
dc.subject | Blastema | |
dc.subject | Cancer | |
dc.subject | Child | |
dc.subject | TP53 | |
dc.subject | Wilms | |
dc.subject.decs | Recurrencia | |
dc.subject.decs | Análisis multivariante | |
dc.subject.decs | Radioterapia | |
dc.subject.decs | Informe de investigación | |
dc.subject.decs | Tasa de supervivencia | |
dc.subject.decs | Supervivencia sin progresión | |
dc.subject.mesh | Adolescent | |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject.mesh | Child | |
dc.subject.mesh | Child, Preschool | |
dc.subject.mesh | Dactinomycin | |
dc.subject.mesh | Disease Progression | |
dc.subject.mesh | Disease-Free Survival | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Infant | |
dc.subject.mesh | Kidney Neoplasms | |
dc.subject.mesh | Male | |
dc.subject.mesh | Neoplasm Recurrence, Local | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Prospective Studies | |
dc.subject.mesh | Survival Rate | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Vincristine | |
dc.subject.mesh | Wilms Tumor | |
dc.title | Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group. | |
dc.type | research article | |
dc.type.hasVersion | SMUR | |
dc.volume.number | 128 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- RISalud_Accesorestringido.pdf
- Size:
- 93.39 KB
- Format:
- Adobe Portable Document Format